AstraZeneca: Gastroesophageal Reflux trials

The registry lists 89 Gastroesophageal Reflux studies with AstraZeneca as lead sponsor. 0 are open to participants now and 15 have results posted.

Phase 1 7Phase 2 12Phase 3 13Phase 4 21No phase 37(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving RabeprazoleCompletedNCT01397084Phase 4Results posted
• Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male SubjectsCompletedNCT01154634Phase 2Results posted
• A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May ExperienceCompletedNCT01043185Phase 2Results posted
• Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)CompletedNCT01019928Phase 2Results posted
• Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPICompletedNCT01005251Phase 2Results posted
• TLESR-impedance Study in PatientsCompletedNCT00743444Phase 2Results posted
• A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)CompletedNCT00734097Phase 4Results posted
• Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) SymptomsCompletedNCT00703534Phase 2Results posted
• Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study USCompletedNCT00660660Phase 4Results posted
• Phase 3/Safety & Efficacy of Esomeprazole in InfantsCompletedNCT00468559Phase 3Results posted
• Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsCompletedNCT00444275Phase 4Results posted
• Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal PatientsCompletedNCT00427635Phase 3Results posted
• Symptom Improvements in Gastroesophageal Reflux Disease (GERD) PatientsCompletedNCT00394472Phase 2Results posted
• Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux AsthmaCompletedNCT00317044Phase 2Results posted
• Esomeprazole (NEXIUM) vs. SurgeryCompletedNCT00251927Phase 3Results posted
• Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.CompletedNCT05267613Phase 3
• S-CEI of Nexium in Paediatric PatientsCompletedNCT03562026
• Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERDCompletedNCT02670642Phase 3
• Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.CompletedNCT02606851
• Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in EgyptCompletedNCT01635959
• The Use of International GerdQ QuestionnaireCompletedNCT01489735
• Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux DiseaseCompletedNCT01432392
• Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an ObservationalCompletedNCT01378338
• A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in GreeceCompletedNCT01215305
• The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) PatientsCompletedNCT01200550
• An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux DiseaseCompletedNCT01134367
• Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking NexiumCompletedNCT01130935
• Non-interventional Study to Evaluate the Change in Symptoms Scores and Treatment Response After 4 Weeks of Proton-Pump Inhibitors (PPI) TreatmentCompletedNCT01103804
• Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal SymptomsCompletedNCT01020890
• Diagnosis and Response to Treatment Using a Reliable Gastroesophageal Reflux Disease (GERD) Questionnaire: An In Clinical Practice StudyCompletedNCT00963144
• Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQCompletedNCT00914342
• The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease QuestionnaireCompletedNCT00901004
• Structured Treatment of Gastroesophageal Reflux in a Company Health Care Setting, -Effect on Quality of Life, Symptoms and ProductivityCompletedNCT00884247
• Renal Impairment StudyCompletedNCT00863161Phase 1
• Partial Response to PPI Treatment: The Cost to Society and the Burden to the Patient - a Study in FranceCompletedNCT00842855
• Evaluation Study of a Management Strategy for Gastroesophageal Reflux Disease (GERD)CompletedNCT00842387
• National Survey on GERD Patients (Adults and Children)CompletedNCT00833573
• 14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter RelaxationsCompletedNCT00813306Phase 1/2
• Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the USCompletedNCT00795093
• Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.CompletedNCT00786773
• Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)CompletedNCT00768443
• Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD PatientsCompletedNCT00768196
• AZD3355 Dose-escalation Study in Healthy MalesCompletedNCT00757419Phase 1
• Esophageal Hypersensitivity Study in Healthy VolunteersCompletedNCT00711048Phase 1
• Asociación Española de Gastroenterologia (Spanish Gastroenterology Association) Gastroesophageal Reflux Disease Guideline - Prospective StudyCompletedNCT00697008
• National Survey on Gastroesophageal Reflux Disease (GERD) PatientsCompletedNCT00695838
• Upper GI Symptoms In Patients Receiving Acetylsalicylic Acid/NSAIDs - NSAIDs Wave 2CompletedNCT00691743
• Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) UseCompletedNCT00691171
• Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient SegmentsCompletedNCT00688675
• Study to Compare Different Formulations of AZD3355CompletedNCT00688402Phase 1
• Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)CompletedNCT00687245Phase 1
• Drug Interaction Study Between AZD3355 and NexiumCompletedNCT00684190Phase 1
• Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in FranceCompletedNCT00681837
• Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)CompletedNCT00637845Phase 4
• Open, Randomized, Two Way Crossover 40mg, Orally and IntravenouslyCompletedNCT00635414Phase 4
• Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERDCompletedNCT00634023
• An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)CompletedNCT00629564Phase 4
• Adult Asthmatics and Acid RefluxCompletedNCT00628953Phase 2
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)CompletedNCT00628342Phase 4
• A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)CompletedNCT00626535Phase 3
• Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and ivCompletedNCT00626262Phase 4
• Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)CompletedNCT00625495Phase 4
• LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)CompletedNCT00567619
• German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-SymptomsCompletedNCT00567021
• Impact of GERD on Daily Life (NIS)CompletedNCT00545883
• What is the Predictive Value of the Reflux Impact ScaleTerminatedNCT00536328
• Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERDCompletedNCT00524355
• Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI DamageCompletedNCT00524329
• The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux PatientsCompletedNCT00524251
• Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERDCompletedNCT00410592Phase 4
• Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for ResponseCompletedNCT00392002Phase 4
• PPI Sequencing StudyCompletedNCT00384592Phase 4
• Symptom Adapted Therapy in GERD PatientsCompletedNCT00343161Phase 4
• Nexium RESPONSE TrialCompletedNCT00318968Phase 4
• PPI Test in GP PatientsCompletedNCT00318084Phase 4
• Validation of RDQ QuestionnaireCompletedNCT00291746Phase 4
• Esomeprazole in PPI Failures - IMPROVECompletedNCT00272701Phase 4
• Sopran - Omeprazole Treatment Versus SurgeryCompletedNCT00256737Phase 3
• ASTERIX: Low Dose ASA and NexiumCompletedNCT00251966Phase 3
• Chest Pain Pilot StudyCompletedNCT00251901Phase 3
• HEARD (Long Term) Study - Histology of the Esophagus in Acid-Related DiseaseCompletedNCT00243724Phase 3
• An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)CompletedNCT00242736Phase 4
• Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDsCompletedNCT00241540Phase 3
• Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDsCompletedNCT00241514Phase 3
• Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent PatientsCompletedNCT00241501Phase 3
• Esomeprazole for Treatment of GERD in Pediatric PatientsCompletedNCT00228527Phase 4
• A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.CompletedNCT00206284Phase 2
• A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.CompletedNCT00206245Phase 2
• NEXIUM® in the Treatment of Moderate and Severe Erosive EsophagitisCompletedNCT00206180Phase 4